Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma

Cell Rep. 2023 Aug 29;42(8):112879. doi: 10.1016/j.celrep.2023.112879. Epub 2023 Aug 2.

Abstract

Neuroblastoma is a lethal childhood solid tumor of developing peripheral nerves. Two percent of children with neuroblastoma develop opsoclonus myoclonus ataxia syndrome (OMAS), a paraneoplastic disease characterized by cerebellar and brainstem-directed autoimmunity but typically with outstanding cancer-related outcomes. We compared tumor transcriptomes and tumor-infiltrating T and B cell repertoires from 38 OMAS subjects with neuroblastoma to 26 non-OMAS-associated neuroblastomas. We found greater B and T cell infiltration in OMAS-associated tumors compared to controls and showed that both were polyclonal expansions. Tertiary lymphoid structures (TLSs) were enriched in OMAS-associated tumors. We identified significant enrichment of the major histocompatibility complex (MHC) class II allele HLA-DOB01:01 in OMAS patients. OMAS severity scores were associated with the expression of several candidate autoimmune genes. We propose a model in which polyclonal auto-reactive B lymphocytes act as antigen-presenting cells and drive TLS formation, thereby supporting both sustained polyclonal T cell-mediated anti-tumor immunity and paraneoplastic OMAS neuropathology.

Keywords: CP: Cancer; CP: Immunology; IgH; TCRB; ataxia; autoimmunity; immune profiling; myoclonus; neuroblastoma; opsoclonus; paraneoplastic; repertoires.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ataxia
  • Autoantibodies
  • Autoimmunity
  • Child
  • Genes, MHC Class II
  • Humans
  • Neuroblastoma* / complications
  • Neuroblastoma* / metabolism
  • Opsoclonus-Myoclonus Syndrome* / complications
  • Opsoclonus-Myoclonus Syndrome* / pathology

Substances

  • Autoantibodies